Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 20;24(18):14334. doi: 10.3390/ijms241814334

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Time- and dose-response curves of administered 8-OH-DPAT in NC and T1DM rats. 8-hydroxy-2-(dipropylamino)tetralin showed no effect in naïve (A–C) rats but elevated nociceptive threshold dose-dependently in diabetic (D–F) rats. 8-hydroxy-2-(dipropylamino)tetralin elevated nociceptive threshold in diabetic in a dose-dependent manner (J–L) but not in control (G–I) rats at 30 min time-point post-administration. WAY100635 antagonizes 8-OH-DPAT’s antinociceptive effects (M–O). Each bar represents means ± SEM of values obtained from five animals/group. * 8-OH-DPAT-treated diabetic animals were significantly different from corresponding diabetic animals at p ≤ 0.05. ** Drug-treated diabetic animals were significantly different from corresponding 8-OH-DPAT-treated animals alone at p ≤ 0.05. Two-way ANOVA was followed by Bonferroni’s post-test, and one-way ANOVA followed by Dunnett’s post-test. Abbreviations: NC—normal control, T1DM—type 1 diabetes mellitus and 8-OH-DPAT—8-hydroxy-2-(dipropylamino)tetralin.